Vitreal Penetration of Oral and Topical Moxifloxacin in Human

Purpoe To invetigate the vitreal penetration of moxifloxacin after oral and topical adminitration. Deign Propective, nonrandomized clinical trial. Method Twenty-four patient were aigned to one of four doing group: control (n = 3), which received no medication; oral (n = 8), which received two 400 mg oral doe of moxifloxacin before urgery; topical (n = 8), which received one drop of topical moxifloxacin 0.5% every 15 minute for the hour preceding urgery; and combined (n = 5), which received two 400 mg oral doe and one drop of topical moxifloxacin 0.5% hourly for 18 hour prior to urgery. Vitreou ample were obtained and analyzed. Reult Control, below quantifiable level; oral, 1.553 ± 0.33 μg/ml; topical, 0.027 μg/ml; and combined, 2.219 ± 0.71 μg/ml. One topical patient developed potoperative endophthalmiti. Concluion In contrat to topical moxifloxacin, oral moxifloxacin achieve ignificant level in the noninflamed human vitreou.